Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference Feb 24, 2026 08:00AM
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results Feb 17, 2026 07:00AM
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 Feb 10, 2026 08:00AM
Krystal Biotech receives FDA RMAT designation for KB707 lung cancer therapy Feb 9, 2026 08:00AM
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer Feb 9, 2026 08:00AM
View Older Stories

Jan 11, 2026 01:00PM Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Jan 8, 2026 04:01PM Krystal Biotech reports gene therapy delivers CFTR protein to CF patients
Jan 8, 2026 04:01PM Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
Jan 7, 2026 04:05PM Krystal Biotech to share KB407 cystic fibrosis trial data
Jan 7, 2026 04:05PM Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
Jan 5, 2026 08:00AM Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
Nov 26, 2025 08:00AM Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
Nov 3, 2025 07:00AM Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results
Oct 21, 2025 08:00AM Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025
Oct 14, 2025 08:03AM Krystal Biotech receives FDA platform technology designation for HSV-1 vector
Oct 14, 2025 08:00AM Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
Sep 15, 2025 08:00AM Krystal Biotech receives FDA approval for expanded VYJUVEK label
Sep 15, 2025 08:00AM Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
Sep 2, 2025 08:00AM Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
Aug 21, 2025 12:14PM Krystal Biotech prioritizes inhaled KB707 for lung cancer treatment
Aug 21, 2025 12:11PM Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
Aug 4, 2025 07:00AM Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
Jul 29, 2025 07:00AM Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
Jul 25, 2025 09:00AM Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
Jul 24, 2025 08:01AM Jeune reports positive Phase 1 results for wrinkle treatment KB304
Jul 24, 2025 08:00AM Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
Jul 9, 2025 07:04AM Krystal Biotech doses first patient in KB801 eye drop gene therapy trial
Jul 9, 2025 07:00AM Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Jun 24, 2025 07:00AM Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Jun 3, 2025 08:00AM Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference
May 7, 2025 08:00AM Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
May 6, 2025 08:00AM Krystal Biotech Announces First Quarter 2025 Financial and Operating Results
Apr 28, 2025 07:05AM Krystal Biotech (KRYS) Announces European Commission Approval of VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Apr 28, 2025 07:00AM Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Apr 24, 2025 08:00AM Krystal Biotech to Present at Upcoming Scientific Conferences
Apr 17, 2025 08:00AM Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
Apr 7, 2025 04:30PM Krystal Biotech (KRYS) Appoints Marc Forth as CEO
Apr 7, 2025 04:30PM Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
Feb 28, 2025 07:45AM Krystal Biotech (KRYS) Receives Positive CHMP Opinion for VYJUVEK
Feb 28, 2025 07:40AM Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Feb 26, 2025 08:00AM Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference
Feb 19, 2025 07:00AM Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
Feb 6, 2025 08:00AM Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Jan 14, 2025 08:04AM Krystal Biotech (KRYS) Appoints Nishant Saxena as Chief Financial Officer
Jan 14, 2025 08:00AM Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
Dec 18, 2024 08:02AM Krystal Biotech (KRYS) Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
Dec 18, 2024 08:00AM Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
Dec 12, 2024 08:00AM Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in
Dec 9, 2024 04:16PM Krystal Biotech (KRYS) Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
Dec 9, 2024 04:15PM Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
Nov 27, 2024 07:00AM Krystal Biotech to Present at Upcoming Investor Conferences
Nov 12, 2024 07:00AM Krystal Biotech to Present at Stifel 2024 Healthcare Conference
Nov 6, 2024 07:00AM Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Nov 4, 2024 08:00AM Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates
Oct 28, 2024 07:00AM Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
View Older Stories